Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 5/20 | 0.62 |
| ▸ | DRD2 | P14416 | 4/20 | 0.62 |
| ▸ | DRD3 | P35462 | 3/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | GFER | P55789 | 1/20 | 0.53 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2774517 | 0.98 | DRD4 (0.64) | DRD4DRD2DRD3HTTKMT2A | |
| SCHEMBL6207632 | 0.85 | CYP2D6 (0.54) | DRD4DRD2DRD3KMT2AMEN1 | |
| SCHEMBL4502913 | 0.83 | CYP1A2 (0.73) | KMT2AMEN1POLBALDH1A1CYP1A2 | |
| SCHEMBL16617729 | 0.83 | DRD4 (0.63) | DRD4DRD2DRD3KMT2AMEN1 | |
| SCHEMBL6842741 | 0.83 | DRD4 (0.59) | DRD4DRD2DRD3KMT2AMEN1 | |
| SCHEMBL885731 | 0.83 | DRD4 (0.59) | DRD4DRD2DRD3KMT2AMEN1 | |
| SCHEMBL2228237 | 0.83 | ALDH1A1 (0.66) | DRD4DRD2DRD3KMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL27770345 | 0.82 | ALDH1A1 (0.71) | KMT2AMEN1POLBALDH1A1GFER | |
| SCHEMBL17269536 | 0.81 | NPSR1 (0.70) | DRD4DRD2DRD3KMT2AMEN1 | |
| SCHEMBL1381550 | 0.81 | ALDH1A1 (0.70) | KMT2AMEN1POLBALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11203582-B2 | Benzamide derivatives for inhibiting endoplasmic reticulum (ER) stress | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2021-12-21 | — | — | US | disclosed |
| US-20200199094-A1 | BENZAMIDE DERIVATIVES FOR INHIBITING ENDOPLASMIC RETICULUM (ER) STRESS | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA | 2020-06-25 | — | — | US | disclosed |
| WO-2018232264-A1 | BENZAMIDE DERIVATIVES FOR INHIBITING ENDOPLASMIC RETICULUM (ER) STRESS | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2018-12-20 | — | — | WO | disclosed |
| EP-2784065-B1 | GLYCINE REUPTAKE INHIBITOR AND USE THEREOF | BEIJING MEDISAN TECHNOLOGY CO LTD (CN) | 2016-10-05 | — | — | EP | disclosed |
| US-8410075-B2 | Mannich base N-oxide drugs | CASCADE PRODRUG INC. (US) | 2013-04-02 | — | — | US | disclosed |
| US-8410075-B2 | Mannich base N-oxide drugs | CASCADE PRODRUG INC. (US) | 2013-04-02 | — | — | US | disclosed |
| US-8410075-B2 | Mannich base N-oxide drugs | CASCADE PRODRUG INC. (US) | 2013-04-02 | — | — | US | disclosed |
| US-20100016252-A1 | Mannich Base N-Oxide Drugs | State of Oregon Acting By and Through The Oregon State Board of Higher Education On Behalf of The U (US) | 2010-01-21 | — | — | US | disclosed |
| US-20100016252-A1 | Mannich Base N-Oxide Drugs | State of Oregon Acting By and Through The Oregon State Board of Higher Education On Behalf of The U (US) | 2010-01-21 | — | — | US | disclosed |
| US-20100016252-A1 | Mannich Base N-Oxide Drugs | State of Oregon Acting By and Through The Oregon State Board of Higher Education On Behalf of The U (US) | 2010-01-21 | — | — | US | disclosed |
| US-4824953-A | Multi-step process for producing 5-hydroxy-N-(6-oxo-piperidyl-methyl)-2-(2,2,2-trifluoro-ethoxy)-benzamide and derivatives | RIKER LABORATORIES, INC. (US) | 1989-04-25 | — | — | US | disclosed |
| US-4822885-A | Cyclopentanone derivatives | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1989-04-18 | — | — | US | disclosed |
| US-4656285-A | Compound 2-acetamidomethyl-6-methoxy-pyridine | RIKER LABORATORIES, INC. (US) | 1987-04-07 | — | — | US | disclosed |
| US-4599434-A | Cyclopentanone derivatives | RIKER LABORATORIES, INC. (US) | 1986-07-08 | — | — | US | disclosed |
| US-4555573-A | Certain 6-benzamidomethyl-2(1H)-pyridone derivatives | RIKER LABORATORIES, INC. (US) | 1985-11-26 | — | — | US | disclosed |
| US-4497954-A | Cyclopentanone derivatives | RIKER LABORATORIES, INC. (US) | 1985-02-05 | — | — | US | disclosed |
| US-4496734-A | Metabolite | RIKER LABORATORIES, INC. (US) | 1985-01-29 | — | — | US | disclosed |
| US-4452983-A | N-(2-PIPERIDYLMETHYL)-2,2,2-TRIFLUOROETHOXY)-BENZAMIDE | RIKER LABORATORIES, INC. (US) | 1984-06-05 | — | — | US | disclosed |
| US-4390716-A | INTERMEDIATES FOR ANTIARRHYTHMIC BENZAMIDE COMPOUNDS | RIKER LABORATORIES, INC. (US) | 1983-06-28 | — | — | US | disclosed |
| US-4339587-A | ANTIARRHYTHMIA AGENTS | RIKER LABORATORIES, INC. (US) | 1982-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200199094-A1 | BENZAMIDE DERIVATIVES FOR INHIBITING ENDOPLASMIC RETICULUM (ER) STRESS | HSPA5, TMBIM6, BAD | DRD4 3257/4885DRD2 3180/4885DRD3 3103/4885 |
| US-11203582-B2 | Benzamide derivatives for inhibiting endoplasmic reticulum (ER) stress | HSPA5, TMBIM6, BAD | DRD4 3257/4885DRD2 3180/4885DRD3 3103/4885 |
| US-20100016252-A1 | Mannich Base N-Oxide Drugs | ASAH2, MAN2B1, NNT | DRD4 2330/4885DRD2 1752/4885DRD3 1205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.